Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Active, not recruiting · NCT04584255 · Registry updated 2026-09-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT04584255 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| GlaxoSmithKline | 294 |
| Johns Hopkins University | 579 |
| Translational Breast Cancer Research Consortium | 19 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Johns Hopkins University | Baltimore | United States | 150 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Mayo Clinic | Rochester | United States | 664 |
| University of Washington / Fred Hutchinson Cancer Center | Seattle | United States | 6 |
| Vanderbilt-Ingram Cancer Center | Nashville | United States | 48 |
| Yale University Cancer Center | New Haven | United States | 6 |